# MCAS claims audit (Andra Sitoianu)

Rating: Early — Mostly animal or cell studies; few or uncontrolled human data
Type: Guide
Updated: 2026-10-16
Canonical: https://heretic.bio/articles/mcas-claims-audit-andra-sitoianu.html

> Andra Sitoianu is a US-licensed naturopathic doctor (ND) whose X account @BioavailableNd and Substack bioavailablend.substack.com reach a large chronic-illness audience (10,000+ paid Substack subscribers per public metadata). She presents clinical frameworks more than she cites primary literature — which is the central reason this audit exists.

## Source identity (from open metadata)

  * **Full name:** Andra Sitoianu
  * **Credentials:** Naturopathic doctor (ND); per Substack metadata, specializes in fertility, nose-to-tail nutrition, food allergy, and "Eat Your Hydration." Self-describes as "independent researcher" and "Food Allergy Mommy."[unverified beyond Substack metadata]
  * **Primary channel:** https://x.com/BioavailableNd
  * **Secondary channel:** https://bioavailablend.substack.com
  * **Substack subscriber count:** 10,000+ (per public Substack metadata)
  * **Public posts on histamine/MCAS:** "Mast Cell Activation Syndrome (MCAS) Protocol" (paid), "From Mouth to Microbiome: How Nickel Can Trigger IBS/IBD Flares" (paid), "The Rosacea Guide" (paid), "The Acne Guide" (paid), "The Lipedema Guide" (paid), "Lipedema: Leaky Gut, Thyroid, Nickel & MCAS" (paid). Multiple X posts on histamine, mast cells, and nnEMF.



## Source quality — library convention applies

Per Source Evaluation Framework, Andra's posts are **Rating 2–3 sources** (clinical observations from a licensed practitioner with patient-facing case volume, but published without peer review, without primary-source citations, and with strong financial alignment — paid Substack content is a direct revenue stream).

Dimension | Rating | Notes  
---|---|---  
Credentials | 4 | Licensed ND; specialty area (food allergy, fertility) consistent with MCAS clinical interest  
Case volume | 3 | Likely high (Substack audience size, X following) but unpublished  
Outcome data | 1 | No systematic outcome data published  
Transparency | 2 | Frames claims as clinical experience; cites almost no papers  
Incentive alignment | 2 | Paid Substack content is direct revenue; she sells clinical frameworks and posts promotional content  
Net | **2–3** | Use as a clinical framework source; verify every strong claim against primary literature  
  
## Claim-by-claim audit

For the full claim table see [Overview - MCAS and Histamine](mcas-and-histamine.html). Summary:

### Claims with strong primary-literature support (Rating 4–5)

  * MCAS exists as a clinical entity (consensus-1 and consensus-2 both ratified)
  * Mast cells release many mediators, not just histamine
  * DAO deficiency drives some HIT symptoms; DAO supplementation helps migraine/urticaria/fibromyalgia
  * Vitamin C reduces blood histamine in depleted subjects
  * Quercetin has mast-cell-stabilizing activity
  * Estrogen directly triggers mast cell degranulation in reproductive tissue
  * Nickel is a metalloestrogen (Martin et al.)
  * Nickel allergy is associated with endometriosis in cohorts
  * Stress / CRH activate mast cells and increase intestinal permeability
  * Low-histamine diet helps HIT subgroup



### Claims that are mechanistic plausibility only (Rating 2–3)

  * "Total load / bucket loss of tolerance" as a measurable model
  * Mold / CIRS → MCAS (overlap real, causal link thin)
  * Nickel as a mast cell activator in non-sensitized hosts
  * DAO capacity falling with age → clinical HIT in older adults
  * Sleep / circadian disruption worsening mast cell activity
  * POTS / hEDS / MCAS clustering (association firmly established, mechanism unclear)
  * Long COVID → MCAS (symptom overlap real, full consensus-1 criteria rare)



### Claims that are speculative or unsupported (Rating 1)

  * ADHD as "a histamine problem"
  * nnEMF as a primary MCAS driver
  * Organotherapy for MCAS
  * Cell salts (biochemic) for MCAS
  * Limbic retraining (DNRS) for MCAS — no MCAS-specific trial
  * Direct causal link from MCAS to: PCOS, GERD, weight gain/lipedema, eczema in general
  * "Beef kidney as a DAO source" via dietary DAO activity



## What is genuinely useful about her work

  1. **The clinical framing is reasonable.** "Total load / bucket" is a useful heuristic for clinicians who have a patient with stacked triggers. It does not require mechanistic proof to be clinically useful.
  2. **She correctly identifies that H1 antihistamines alone are insufficient for MCAS.** This matches mainstream MCAS literature and is worth patients knowing.
  3. **The emphasis on mold, nickel, hormones, and stress as stacked triggers** is consistent with the broad literature showing mast cells respond to all of these signals.
  4. **Her Substack is a useful discovery channel** for what chronic-illness communities are currently discussing. It is not a substitute for primary literature.



## What is problematic

  1. **Almost no primary literature cited.** Claims are presented as clinical truth without supporting PMIDs. This is the most important limitation — patients and clinicians cannot audit the underlying evidence.
  2. **Paywall on the protocol post.** The "MCAS Protocol" post (the central document for her MCAS framework) is gated; the public preview describes "dozens of chemical messengers beyond histamine" but does not give specific dosing, sequencing, or the underlying rationale.
  3. **Broader-than-supported claims about MCAS driving PCOS, ADHD, GERD, lipedema, etc.** Each of these has at most fragmentary evidence.
  4. **Speculative interventions are presented alongside mainstream ones.** Organotherapy, cell salts, and limbic retraining are presented without distinguishing them from evidence-based interventions.
  5. **No systematic outcome data.** this library's Source Evaluation Framework flags this as Rating 1.



## Practical Notes (library usage)

  * Use Andra's work as a _clinical framework_ and a discovery channel for what chronic-illness communities are paying attention to.
  * Always cross-check specific claims against the primary references listed in [Overview - MCAS and Histamine](mcas-and-histamine.html), [MCAS - Diagnostic Criteria and Differential](mcas-diagnostic-criteria-and-differential.html), [DAO and Histamine Degradation](dao-and-histamine-degradation.html), and [MCAS - Drivers and Comorbidities](mcas-drivers-and-comorbidities.html).
  * Be especially skeptical of the "MCAS underlies [long condition list]" framing — most of these connections are mechanistic plausibility or single-cohort association, not demonstrated causality.
  * Treat her protocols as a _layered, total-load approach_ that may help some patients; not as a validated treatment standard.



## Notes

  * A 2024 single-center study of 703 suspected MCAS patients found that only a small minority met consensus-1 MCAS criteria, with most having alternative or comorbid explanations. This is consistent with the experience that the broad consensus-2 framing produces many false-positive diagnoses.[128]
  * The chronic-illness community often anchors on a small set of influential practitioners (Andra, Neil Nathan, Jill Carnahan, Ben Weiler for mainstream, Afrin for consensus-2). Each practitioner has a different bias; this library should record the bias, not just the recommendation.

## Sources

1. PubMed 38056692 (PubMed 38056692)